Zai Lab (09688) saw an increase of over 4% in morning trading. At the time of writing, the stock was up 4.82%, trading at HK$15.88 with a turnover of HK$288 million.

On April 1, Zai Lab announced a global clinical research collaboration with Amgen. The partnership aims to evaluate Zai Lab's clinical-stage antibody-drug conjugate (ADC) zocilurtatug pelitecan (zoci, formerly known as ZL-1310), which targets delta-like ligand 3 (DLL3), in combination with Amgen's IMDELLTRA® (tarlatamab), a bispecific T-cell engager (BiTE®) therapy targeting DLL3, for the treatment of patients with extensive-stage small cell lung cancer (ES-SCLC).

As part of the agreement, Amgen will sponsor a global Phase 1b study to assess the safety and efficacy of zoci in combination with IMDELLTRA® in ES-SCLC patients. Zai Lab will retain full ownership of zoci and will supply the investigational drug for the clinical study.